Why did Fiserv lead the S&P 500 today?
How did Trump’s ceasefire impact global stocks?
Why are oil prices falling after Iran strikes?
What caused Amazon’s Alexa AI upgrade backlash?
How will Mastercard’s stablecoin partnerships affect payments?
Why did McDonald’s end its partnership with Krispy Kreme?
How are Tesla robotaxis affecting federal safety scrutiny?
Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle
psychedelicalpha.com/news/compass-pathways-psilocybin-clears-first-phase-3-hurdle
This morning, Compass Pathways shared a readout from the first of two Phase 3 trials investigating its synthetic psilocybin candidate, COMP360, in treatment-resistant depression (TRD). That makes it the first Phase 3 study of a classical psychedelic to print data.
The company reports…
This story appeared on psychedelicalpha.com, 2025-06-24 11:26:23.352000.